Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 22;13:185–196. doi: 10.2147/DMSO.S232279

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Luo et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

DHA inhibits NF-κB activation through deacetylation of p65 mediated by Sirt1. (A) A representative set of data from three independent experiments is illustrated (left panel) and quantification histograms (right panel) of Sirt1, Ac-p65, P-p65 and p65 expressions in HepG2 cells. Values are mean±S.E.M. (n = 3, *p < 0.05; **p < 0.01 versus Ctrl cells). (B) Proposed model for DHA regulating hepatic steatosis in liver. DHA inhibits HFD-induced downregulation of Sirt1. On the one hand, accumulation of Sirt1 inhibits NF-kB activation through deacetylating p65. Inactivated NF-kB reduces pro-inflammation, leading to ameliorated hepatic steatosis. On the other hand, increased Sirt1 promotes β-oxidation and TAG export resulting in decreased hepatic steatosis.